Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation

Sun, Juan, Huangfu, Zhenyuan, Yang, Jiangtao, Wang, Guanglin, Hu, Kuan, Gao, Mingyuan, Zhong, Zhiyuan·2022·Advanced Drug Delivery Reviews
DOI 10.1016/j.addr.2022.114538

Cites (242)

Items 201–242 of 242

  1. 188W/188Re Generator System and Its Therapeutic Applications
    Alessandra Boschi, Licia Uccelli, M. Pasquali · 2014 · Journal of Chemistry
  2. Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated β-Emitter Peptide Receptor Radionuclide Therapy
    Jingjing Zhang, Harshad Kulkarni, Richard Paul Baum · 2019 · Clinical Nuclear Medicine
  3. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy
    Stephen A. Graves, Robert F. Hobbs · 2020 · Seminars in Radiation Oncology
  4. Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE
    Étienne Rousseau, Joseph Lau, Zhengxing Zhang · 2018 · Nuclear Medicine and Biology
  5. Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook
    Amy L. Vāvere, Peter J. H. Scott · 2017 · Seminars in Nuclear Medicine
  6. The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging
    Ann-Christin Eder, Mohamed Aymen Omrane, Sven Stadlbauer et al. · 2021 · European Journal of Nuclear Medicine and Molecular Imaging
  7. Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somastostatin-Receptor-Based Theranostic Agent
    Nilantha Bandara, Orit Jacobson, Cedric Mpoy · 2018 · Bioconjugate Chemistry
  8. Development of PSMA-1007-Related Series of 18F-Labeled Glu-Ureido-Type PSMA Inhibitors
    Jens Cardinale, Mareike Roscher, Martin K.-H. Schäfer et al. · 2020 · Journal of Medicinal Chemistry
  9. Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models
    Sofia H.L. Frost, Shani L. Frayo, Brian W. Miller, Johnnie J. Orozco, Garrett C. Booth, Mark D. Hylarides, Yukang Lin, Damian J. Green, Ajay K. Gopal, John M. Pagel et al. · 2015 · PLoS ONE
  10. Dose escalation of an Evans blue–modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors
    Qingxing Liu, Yuejuan Cheng, Jie Zang · 2019 · European Journal of Nuclear Medicine and Molecular Imaging
  11. 68Ga-Pentixafor PET/CT demonstrating higher CXCR4 density in small cell lung carcinoma than in non-small cell variant
    Ankit Watts, Baljinder Singh, Rajender Kumar Basher, Harmandeep Singh, Amanjit Bal, Rakesh K. Kapoor, Sunil Kumar Arora, Hans Jürgen Wester, Bhagwant Rai Mittal, Digambar Behera · 2017 · European Journal of Nuclear Medicine and Molecular Imaging
  12. PET Imaging of VEGFR with a Novel 64Cu-Labeled Peptide
    Kuan Hu, Jingjie Shang, Lin Xie · 2020 · ACS Omega
  13. Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
    Yubin Miao, Thomas P. Quinn · 2020 · Journal of Nuclear Medicine
  14. Preclinical Characterization of 86/90Y-NM600 in a Variety of Murine and Human Cancer Tumor Models
    Joseph J. Grudzinski, Reinier Hernandez, Ian R. Marsh · 2019 · Journal of Nuclear Medicine
  15. Solid‐tumor radionuclide therapy dosimetry: New paradigms in view of tumor microenvironment and angiogenesis
    Xuping Zhu, Matthew R. Palmer, Gerassimos Mike Makrigiorgos · 2010 · Medical Physics
  16. Molecular Imaging of Chemokine Receptor CXCR4 in Non–Small Cell Lung Cancer Using 68Ga-Pentixafor PET/CT
    Thorsten Derlin, Danny David Jonigk, Johann K Bauersachs · 2016 · Clinical Nuclear Medicine
  17. Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors
    Bianka B. Saravana-Bawan, Amandeep Bajwa, John Paterson · 2019 · Clinical Nuclear Medicine
  18. Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities
    Peter Herhaus, Stefan Habringer, Tibor Vág · 2017 · EJNMMI Research
  19. Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
    Jakob Albrecht, Samantha Exner, Carsten Grötzinger, Sonal Prasad, Frank Konietschke, Nicola Beindorff, Anja Andrea Kühl, Vikas Prasad, Winfried Brenner, Eva J. Koziolek · 2020 · Journal of Nuclear Medicine
  20. 131I-IITM and 211At-AITM: Two Novel Small-Molecule Radiopharmaceuticals Targeting Oncoprotein Metabotropic Glutamate Receptor 1
    Lin Xie, Masayuki Hanyu, Masayuki Fujinaga et al. · 2019 · Journal of Nuclear Medicine
  21. Imaging PARP with [18F]rucaparib in pancreatic cancer models
    Chung Ying Chan, Zijun Chen, Gianluca Destro, Mathew Veal, Doreen Lau, Edward S. O’Neill, Gemma Dias, Michael J. Mosley, Veerle Kersemans, Florian Guibbal et al. · 2022 · European Journal of Nuclear Medicine and Molecular Imaging
  22. Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules
    Ann-Christin Eder, Martin K.-H. Schäfer, Jana Schmidt, Ulrike Bauder‐Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka, Matthias Eder · 2021 · Journal of Nuclear Medicine
  23. Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint
    Kuan Hu, Lin Xie, Masayuki Hanyu · 2020 · RSC Chemical Biology
  24. 211At-Labeled Polymer Nanoparticles for Targeted Radionuclide Therapy of Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR)-Overexpressed Cancer
    Xiumin Shi, Qing Li, Lulu Zhang, Masayuki Hanyu, Lin Xie, Kuan Hu, Kotaro Nagatsu, Chuan Zhang, Zhengcan Wu, Feng Wang et al. · 2021 · Bioconjugate Chemistry
  25. 571P Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP)
    Dirk Zboralski, Frank Osterkamp, Andrew D. Simmons et al. · 2020 · Annals of Oncology
  26. Development of a Stable Peptide-Based PET Tracer for Detecting CD133-Expressing Cancer Cells
    Kuan Hu, Xiaohui Ma, Lin Xie et al. · 2021 · ACS Omega
  27. PSMA: a potential therapeutic target in RCC
    Michael A. Gorin, Steven P. Rowe · 2017 · Nature Reviews Urology
  28. 99mTc-Hynic-TOC imaging in the diagnostic of neuroendocrine tumors
    Knut Liepe, Andreas Becker · 2018 · World Journal of Nuclear Medicine
  29. Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical
    Arijit Kumar Ghosh, Karen Woolum, Shankaran Kothandaraman · 2019 · Molecules
  30. Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
    Zhao-Hui Jin, Atsushi B. Tsuji, Mélissa Degardin et al. · 2020 · Clinical Cancer Research
  31. Use of 68Ga-FAPI PET/CT for Evaluation of Peritoneal Carcinomatosis Before and After Cytoreductive Surgery
    Liang Zhao, Yizhen Pang, Jihong Wei · 2021 · Clinical Nuclear Medicine
  32. Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
    Heribert Hänscheid, Philipp E. Hartrampf, Andreas Schirbel · 2021 · European Journal of Nuclear Medicine and Molecular Imaging
  33. Is It Time to Widen the Use of Somatostatin Analogs in Neuroendocrine Tumors?
    Kjell E. Öberg · 2009 · Journal of Clinical Oncology
  34. Preparation and Preliminary Evaluation of Neurotensin Radiolabelled with 68Ga and 177Lu as Potential Theranostic Agent for Colon Cancer
    Radu Anton Leonte, Livia Chilug, Radu M. Serban · 2021 · Pharmaceutics
  35. How Should the FDA Review Diagnostic Radiopharmaceuticals?
    Carol S. Marcus · 2017 · Journal of Nuclear Medicine
  36. Synthesis and preliminary evaluation of novel 11C-labeled GluN2B-selective NMDA receptor negative allosteric modulators
    Jiyun Sun, Katsushi Kumata, Zhen Chen et al. · 2020 · Acta Pharmacologica Sinica
  37. Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone
    Esther W. Bouman-Wammes, John M. H. de Klerk, Haiko J. Bloemendal · 2018 · Clinical Genitourinary Cancer
  38. New radiotracer shows impressive diagnostic potential
    Elizabeth Gourd · 2019 · The Lancet Oncology
  39. Targeted Radioligand Approved for Metastatic Prostate Cancer
    Howard D. Larkin · 2022 · JAMA
  40. Octreotide
    Z. Tulassay, L Flautner, Imre Fehérvári · 1992 · The Lancet
  41. Lanreotide delays progression of neuroendocrine tumours
    Judith A Gilbert · 2014 · The Lancet Oncology
  42. Enhancing Tumor Uptake for 177Lu-Labeled MC1R Targeting Radioligands by Combining N-Methylations with an Albumin Binder
    Chengcheng Zhang, Zhengxing Zhang, Jutta Zeisler · 2020 · Journal of Nuclear Medicine